Sarah Morgan

Dr. Sarah Morgan


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DNDavid P. Nichols
David P. Nichols
SMSarah Morgan
Sarah Morgan
MSMichelle Skalland
Michelle Skalland
AVAnh T. Vo
Anh T. Vo
JDJill M. Van Dalfsen
Jill M. Van Dalfsen
PSPradeep K. Singh
Pradeep K. Singh
Background. Lung infections are among the most consequential manifestations of cystic fibrosis (CF) and are associated with reduced lung function and shortened survival. Drugs called CF transmembrane conductance regulator (CFTR) modulators improve activity of dysfunctional CFTR channels, which is the physiological defect causing CF. However, it is unclear how improved CFTR activity affects CF lung infections. Methods. We performed a prospective, multicenter, observational study to measure the effect of the newest and most effective CFTR modulator, elexacaftor/tezacaftor/ivacaftor (ETI), on CF lung infections. We studied sputum from 236 people with CF during their first 6 months of ETI using bacterial cultures, PCR, and sequencing. Results. Mean sputum densities of Staphylococcus aureus, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Achromobacter spp., and Burkholderia spp. decreased by 2–3 log10 CFU/mL after 1 month of ETI. However, most participants remained culture positive for the pathogens cultured from their sputum before starting ETI. In those becoming culture negative after ETI, the pathogens present before treatment were often still detectable by PCR months after sputum converted to culture negative. Sequence-based analyses confirmed large reductions in CF pathogen genera, but other bacteria detected in sputum were largely unchanged. ETI treatment increased average sputum bacterial diversity and produced consistent shifts in sputum bacterial composition. However, these changes were caused by ETI-mediated decreases in CF pathogen abundance rather than changes in other bacteria. Conclusions. Treatment with the most effective CFTR modulator currently available produced large and rapid reductions in traditional CF pathogens in sputum, but most participants remain infected with the pathogens present before modulator treatment. Trial Registration. ClinicalTrials.gov NCT04038047. Funding. The Cystic Fibrosis Foundation and the NIH.

27 August 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SMSarah Morgan
Sarah Morgan
ECEllis Coulter
Ellis Coulter
HBHannah L. Betts
Hannah L. Betts
GSGeorge M. Solomon
George M. Solomon
JCJohn P. Clancy
John P. Clancy
PSPradeep K. Singh
Pradeep K. Singh

22 December 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
SMSarah Morgan
Sarah Morgan
SDSamantha L. Durfey
Samantha L. Durfey
SRSumedha Ravishankar
Sumedha Ravishankar
PJPeter Allan Jorth
Peter Allan Jorth
WNWendy Ni
Wendy Ni
PSPradeep K. Singh
Pradeep K. Singh
A hallmark of chronic bacterial infections is the long-term persistence of 1 or more pathogen species at the compromised site. Repeated detection of the same bacterial species can suggest that a single strain or lineage is continually present. However, infection with multiple strains of a given species, strain acquisition and loss, and changes in strain relative abundance can occur. Detecting strain-level changes and their effects on disease is challenging because most methods require labor-intensive isolate-by-isolate analyses, and thus, only a few cells from large infecting populations can be examined. Here, we present a population-level method for enumerating and measuring the relative abundance of strains called population multi-locus sequence typing (PopMLST). The method exploits PCR amplification of strain-identifying polymorphic loci, next-generation sequencing to measure allelic variants, and informatic methods to determine whether variants arise from sequencing errors or low-abundance strains. These features enable PopMLST to simultaneously interrogate hundreds of bacterial cells that are cultured en masse from patient samples or are present in DNA directly extracted from clinical specimens without ex vivo culture. This method could be used to detect epidemic or super-infecting strains, facilitate understanding of strain dynamics during chronic infections, and enable studies that link strain changes to clinical outcomes.